MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, announced it has closed a £7 million GBP Series A financing round, led by Mercia Ventures.
MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, announced it has closed a £7 million GBP Series A financing round, led by Mercia Ventures.